A Phase I Study of Olaparib and Low-Dose Radiation Therapy for Small Cell Lung Cancer

Full Title

A Phase I Study of Olaparib and Low Dose Thoracic Radiotherapy for Extensive Stage Small Cell Lung Cancer

Purpose

The standard treatment for advanced small cell lung cancer (SCLC) is chemotherapy followed by radiation therapy to the chest to reduce the risk of lung cancer recurrence, and also preventive radiation to the brain to lower the chance that the cancer will spread there. In this study, researchers are finding the highest dose of the drug olaparib that can be given safely with low-dose radiation therapy to the chest in patients with SCLC who have had chemotherapy.

Olaparib is a type of medication called a PARP inhibitor, which researchers believe can slow down the process cancer cells use to repair their DNA. Cancer cells need to repair their DNA to survive and grow. Radiation therapy works by damaging the DNA in cancer cells. Therefore, blocking the DNA repair process with olaparib and giving radiation therapy at the same time may be more effective against SCLC than radiation alone.

Olaparib is used to treat ovarian cancer; its use in this study is considered investigational. It is taken orally (by mouth).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have extensive stage SCLC and have completed induction chemotherapy, with no evidence of continued cancer growth.
  • At least 3 weeks must pass between the completion of chemotherapy and entry into the study.
  • Patients may not have previously received radiation therapy to the chest (although prior breast cancer radiation is permitted).
  • Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Andreas Rimner at 212-639-6025.

Protocol

18-195

Phase

I

Disease Status

Newly Diagnosed & Relapsed/Refractory

Investigator

Co-Investigators